<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="14bf5106-3b8c-4375-8466-c158c8f8f614"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS.<br/>METFORMIN hydrochloride extended-release tablets for oral use <br/>Initial U.S. Approval: 1995</title>
   <effectiveTime value="20250310"/>
   <setId root="1200ea71-8a9e-4e49-bb77-7d9fe0d84ae7"/>
   <versionNumber value="11"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="089153071" root="1.3.6.1.4.1.519.1"/>
            <name>Lupin Pharmaceuticals, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="675923163" root="1.3.6.1.4.1.519.1"/>
                  <name>LUPIN LIMITED</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="650759348" root="1.3.6.1.4.1.519.1"/>
                        <name>LUPIN LIMITED</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68180-338" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68180-339" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68180-338" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68180-339" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="677600414" root="1.3.6.1.4.1.519.1"/>
                        <name>LUPIN LIMITED</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68180-338" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68180-339" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68180-338" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68180-339" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="d7f6dd48-e1c1-43e8-9e6e-a287d1ec2f70"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL Product Data Elements Section"/>
               <effectiveTime value="20250310"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="68180-338" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>METFORMIN HYDROCHLORIDE</name>
                        <formCode code="C42927" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, EXTENDED RELEASE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>METFORMIN HYDROCHLORIDE</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="500" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="786Z46389E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METFORMIN HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="9100L32L2N" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>METFORMIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="68180-338-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20160201"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="500" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="68180-338-02" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20400101"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="1000" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="68180-338-03" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20400101"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA091664" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20160201"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE">
                              <originalText>WHITE TO OFF WHITE</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL">
                              <originalText>BI CONVEX</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="PQ" value="18" unit="mm"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="INT" value="1"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">L41;LU</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="68180-339" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>METFORMIN HYDROCHLORIDE</name>
                        <formCode code="C42927" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, EXTENDED RELEASE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>METFORMIN HYDROCHLORIDE</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="1000" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="786Z46389E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METFORMIN HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="9100L32L2N" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>METFORMIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="90" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="68180-339-09" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20160201"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="68180-339-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20400101"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="500" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="68180-339-02" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20400101"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA091664" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20160201"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE">
                              <originalText>WHITE TO OFF WHITE</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL">
                              <originalText>BI CONVEX</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="PQ" value="21" unit="mm"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="INT" value="1"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">L42;LU</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID256">
               <id root="d92bee3a-c6a4-417f-aa43-70252ed6b210"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>WARNING: LACTIC ACIDOSIS</title>
               <effectiveTime value="20230303"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID258">
                           <content styleCode="bold">WARNING: LACTIC ACIDOSIS</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">See full prescribing information for complete boxed warning</content>
                           </content>
                        </paragraph>
                        <list listType="unordered" ID="ID259" styleCode="Disc">
                           <item>
                              <content styleCode="bold">Postmarketing cases of metformin-associated lactic      acidosis have resulted in death, hypothermia, hypotension, and resistant      bradyarrhythmias. Symptoms included malaise, myalgias, respiratory      distress, somnolence, and abdominal pain. Laboratory abnormalities      included elevated blood lactate levels, anion gap acidosis, increased      lactate/pyruvate ratio; and metformin plasma levels generally &gt;5      mcg/mL. (<linkHtml href="#ID299">5.1</linkHtml>)</content>
                           </item>
                           <item>
                              <content styleCode="bold">Risk factors include renal impairment, concomitant use      of certain drugs, age â‰¥ 65 years old, radiological studies with      contrast, surgery and other procedures, hypoxic states, excessive alcohol      intake, and hepatic impairment. Steps to reduce the risk of and manage      metformin-associated lactic acidosis in these high risk groups are      provided in the Full Prescribing Information. (<linkHtml href="#ID299">5.1</linkHtml>) </content>
                           </item>
                           <item>
                              <content styleCode="bold">If lactic acidosis is suspected, discontinue metformin      hydrochloride extended-release tablet and institute general supportive      measures in a hospital setting. Prompt hemodialysis is recommended. (<linkHtml href="#ID299">5.1</linkHtml>) </content>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID260">
                     <id root="3f112557-3042-4162-b467-ea4f01d16afe"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID261">
                           <content styleCode="bold">Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin-associated lactic acidosis was characterized by elevated blood lactate levels (&gt; 5 mmol/Liter), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate/pyruvate ratio, and metformin plasma levels generally &gt;5 mcg/mL [<content styleCode="italics">see WARNINGS AND PRECAUTIONS (<linkHtml href="#ID299">5.1</linkHtml>)</content>].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, and hepatic impairment.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk groups are provided in the full prescribing information [<content styleCode="italics">see DOSAGE AND ADMINISTRATION (<linkHtml href="#ID276">2.2</linkHtml>)</content>, <content styleCode="italics">CONTRAINDICATIONS (<linkHtml href="#ID289">4</linkHtml>), WARNINGS AND PRECAUTIONS (<linkHtml href="#ID299">5.1</linkHtml>), and DRUG INTERACTIONS (<linkHtml href="#ID321">7</linkHtml>)].</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">If metformin-associated lactic acidosis is suspected, immediately discontinue metformin hydrochloride extended-release tablet and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended <content styleCode="italics">[see WARNINGS AND PRECAUTIONS (<linkHtml href="#ID299">5.1</linkHtml>)]</content>.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20181204"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID265">
               <id root="f373a9ea-ca82-44de-aa5a-ad6a5b713231"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <effectiveTime value="20191107"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID267">Metformin hydrochloride extended-release tablet is a biguanide indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. (<linkHtml href="#ID265">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID268">
                     <id root="509c6a18-0c5e-46b7-9096-6612856bf502"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID269">Metformin hydrochloride extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.</paragraph>
                     </text>
                     <effectiveTime value="20181203"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID270">
               <id root="d6e7032b-2f42-4308-a3d7-b2c2ee6fe8a1"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20181204"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID402" styleCode="Disc">
                           <item>Starting dose: 500 mg orally once daily with the evening      meal (<linkHtml href="#ID274">2.1</linkHtml>)</item>
                           <item>Increase the dose in increments of 500 mg every 1 to 2      weeks, up to a maximum of 2,000 mg once daily with the evening meal.      (<linkHtml href="#ID274">2.1</linkHtml>)</item>
                           <item>Patients receiving metformin hydrochloride (HCl) tablets      may be switched to metformin hydrochloride extended-release tablets once      daily at the same total daily dose, up to 2,000 mg once daily.      (<linkHtml href="#ID274">2.1</linkHtml>)</item>
                           <item>Swallow metformin hydrochloride extended-release tablets      whole and never crush, cut or chew. (<linkHtml href="#ID274">2.1</linkHtml>)</item>
                        </list>
                        <paragraph ID="ID415">
                           <content styleCode="underline">Renal Impairment:</content>
                        </paragraph>
                        <list listType="unordered" ID="ID416" styleCode="Disc">
                           <item>Prior to initiation, assess renal function with estimated glomerular filtration rate (eGFR) (<linkHtml href="#ID276">2.2</linkHtml>).<list listType="unordered" styleCode="Circle">
                                 <item>Do not use in patients with eGFR below 30 mL/minute/1.73 m<sup>2</sup>.</item>
                                 <item>Initiation is not recommended in patients with eGFR between 30 to 45 mL/minute/1.73 m<sup>2</sup>.<sup/>
                                 </item>
                                 <item>Assess risk/benefit of continuing metformin hydrochloride if eGFR falls below 45 mL/minute/1.73 m<sup>2</sup>.</item>
                                 <item>Discontinue if eGFR falls below 30 mL/minute/1.73 m<sup>2</sup>.</item>
                              </list>
                           </item>
                        </list>
                        <paragraph ID="ID417">
                           <content styleCode="underline">Discontinuation for Iodinated Contrast Imaging Procedures:</content>
                        </paragraph>
                        <list listType="unordered" ID="ID418" styleCode="Disc">
                           <item>Metformin hydrochloride      extended-release tablets may need to be discontinued at time of, or prior      to, iodinated contrast imaging procedures (<linkHtml href="#ID280">2.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID273">
                     <id root="e2343c62-b454-448d-92a0-3714dee660d0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <effectiveTime value="20170621"/>
                  </section>
               </component>
               <component>
                  <section ID="ID274">
                     <id root="3e83b767-9b0a-4909-b97d-7793e4df9371"/>
                     <title>2.1 Adult Dosage and Administration</title>
                     <text>
                        <list listType="unordered" ID="ID419" styleCode="Disc">
                           <item>The recommended starting dose      of metformin hydrochloride extended-release tablets is 500 mg orally once      daily with the evening meal.</item>
                           <item>Increase the dose in increments      of 500 mg every 1 to 2 weeks on the basis of glycemic control and      tolerability, up to a maximum of 2,000 mg once daily with the evening      meal.</item>
                           <item>Patients receiving metformin      hydrochloride (HCl) may be switched to metformin hydrochloride      extended-release tablets once daily at the same total daily dose, up to      2,000 mg once daily.</item>
                           <item>Swallow metformin hydrochloride      extended-release tablets whole and never crush, cut or chew.</item>
                           <item>If a dose of metformin      hydrochloride extended-release tablets is missed, instruct patients not to      take two doses the same day and to resume their usual dose of metformin      hydrochloride extended-release tablets with the next schedule dose.</item>
                        </list>
                     </text>
                     <effectiveTime value="20181203"/>
                  </section>
               </component>
               <component>
                  <section ID="ID276">
                     <id root="7d1b24e8-7e82-46ba-8074-c50095df3acb"/>
                     <title>2.2 Recommendations for Use in Renal Impairment</title>
                     <text>
                        <list listType="unordered" ID="ID420" styleCode="Disc">
                           <item>Assess renal function prior to      initiation of metformin hydrochloride extended-release tablets and      periodically thereafter.</item>
                           <item>Metformin hydrochloride      extended-release tablets are contraindicated in patients with an estimated      glomerular filtration rate (eGFR) below 30 mL/minute/1.73 m<sup>2</sup>.</item>
                           <item>Initiation of metformin      hydrochloride extended-release tablets in patients with an eGFR between 30      to 45 mL/minute/1.73 m<sup>2</sup>is not recommended.</item>
                           <item>In patients taking metformin      hydrochloride extended-release tablets whose eGFR later falls below 45      mL/min/1.73 m<sup>2</sup>, assess the benefit risk of continuing therapy.</item>
                           <item>Discontinue metformin      hydrochloride extended-release tablets if the patient's eGFR later      falls below 30 mL/minute/1.73 m<sup>2</sup>
                              <content styleCode="italics">[see CONTRAINDICATIONS (<linkHtml href="#ID289">4</linkHtml>)      and WARNINGS AND PRECAUTIONS (<linkHtml href="#ID299">5.1</linkHtml>)]</content> .</item>
                        </list>
                     </text>
                     <effectiveTime value="20181203"/>
                  </section>
               </component>
               <component>
                  <section ID="ID280">
                     <id root="ab902cc6-4ea2-4fcb-bebb-f9127e32a5cd"/>
                     <title>2.3 Discontinuation for Iodinated Contrast Imaging Procedures</title>
                     <text>
                        <paragraph ID="ID281">Discontinue metformin hydrochloride extended-release tablets at the time of, or prior to, an iodinated contrast imaging procedure in patients with an eGFR between 30 and 60 mL/minute/1.73 m<sup>2</sup>; in patients with a history of liver disease, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast. Re-evaluate eGFR 48 hours after the imaging procedure; restart metformin hydrochloride extended-release tablets if renal function is stable <content styleCode="italics">[see WARNINGS AND PRECAUTIONS (<linkHtml href="#ID299">5.1</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20181204"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID284">
               <id root="3aa2baaf-32fd-4735-9bc2-1d447719b9e8"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <effectiveTime value="20181203"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID286">Metformin Hydrochloride Extended-Release Tablets: 500 mg and 1,000 mg (<linkHtml href="#ID284">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID287">
                     <id root="571fcf0d-0ed1-4096-a4aa-16a93e2ae4b3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID288">Metformin hydrochloride extended-release tablets, 500 mg are available as white to off-white, oval shaped, biconvex coated tablet, debossed with "L41" on one side and "LU" on the other side.</paragraph>
                        <paragraph>Metformin hydrochloride extended-release tablets, 1,000 mg are available as white to off-white, oval shaped, biconvex coated tablet, debossed with "L42" on one side and "LU" on the other side.</paragraph>
                     </text>
                     <effectiveTime value="20181203"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID289">
               <id root="c06db39a-e809-460f-95d8-984886194aa4"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <effectiveTime value="20250305"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID291" styleCode="Disc">
                           <item>Severe renal impairment: (eGFR below 30mL/minute/1.73 m<sup>2</sup>) (<linkHtml href="#ID289">4</linkHtml>, <linkHtml href="#ID299">5.1</linkHtml>)</item>
                           <item>Known hypersensitivity to metformin (<linkHtml href="#ID289">4</linkHtml>)</item>
                           <item>Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma (<linkHtml href="#ID289">4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID292">
                     <id root="25d6cdb5-aa9f-4ca1-8d0f-989cf8af8d70"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID293">Metformin hydrochloride extended-release tablets are contraindicated in patients with:</paragraph>
                        <list listType="unordered" ID="ID294" styleCode="Disc">
                           <item>Severe renal impairment (eGFR below 30mL/minute/1.73 m<sup>2</sup>) <content styleCode="italics">[see WARNINGS AND PRECAUTIONS (<linkHtml href="#ID299">5.1</linkHtml>)]</content> .</item>
                           <item>Known hypersensitivity to metformin.</item>
                           <item>Acute or chronic metabolic acidosis, including diabetic      ketoacidosis, with      or without coma.</item>
                        </list>
                     </text>
                     <effectiveTime value="20181204"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID295">
               <id root="48fa7043-ede5-482f-adb5-5470be30ea2c"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250305"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID297" styleCode="Disc">
                           <item>Lactic Acidosis: See boxed warning.      (<linkHtml href="#ID299">5.1</linkHtml>)</item>
                           <item>Vitamin B12 Deficiency: Metformin may lower vitamin B12      levels. Monitor hematologic parameters annually and vitamin B12 at 2 to 3      year intervals and manage any abnormalities.      (<linkHtml href="#ID303">5.2</linkHtml>)</item>
                           <item>Hypoglycemia with Concomitant Use with Insulin and Insulin      Secretagogues: Increased risk of hypoglycemia when used in combination      with insulin and/or an insulin secretagogue. Lower dose of insulin or      insulin secretagogue may be required. (<linkHtml href="#ID305">5.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID298">
                     <id root="8df13bd5-dc5c-4cfc-bd74-33d541dac3ea"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <effectiveTime value="20170621"/>
                  </section>
               </component>
               <component>
                  <section ID="ID299">
                     <id root="e7937a3d-ff89-4187-befb-fb060d2dc8e9"/>
                     <title>5.1 Lactic Acidosis</title>
                     <text>
                        <paragraph ID="ID300">There have been postmarketing cases of metformin-associated lactic acidosis, including fatal cases. These cases had a subtle onset and were accompanied by nonspecific symptoms such as malaise, myalgias, abdominal pain, respiratory distress, or increased somnolence; however, hypothermia, hypotension and resistant bradyarrhythmias have occurred with severe acidosis. Metformin-associated lactic acidosis was characterized by elevated blood lactate concentrations (&gt;5 mmol/Liter), anion gap acidosis (without evidence of ketonuria or ketonemia), and an increased lactate/pyruvate ratio; metformin plasma levels were generally &gt;5 mcg/mL. Metformin decreases liver uptake of lactate increasing lactate blood levels which may increase the risk of lactic acidosis, especially in patients at risk.</paragraph>
                        <paragraph ID="ID409">If metformin-associated lactic acidosis is suspected, general supportive measures should be instituted promptly in a hospital setting, along with immediate discontinuation of metformin hydrochloride extended-release tablets. In metformin hydrochloride extended-release tablets-treated patients with a diagnosis or strong suspicion of lactic acidosis, prompt hemodialysis is recommended to correct the acidosis and remove accumulated metformin (metformin HCl is dialyzable, with a clearance of up to 170 mL/minute under good hemodynamic conditions). Hemodialysis has often resulted in reversal of symptoms and recovery.</paragraph>
                        <paragraph ID="ID410">Educate patients and their families about the symptoms of lactic acidosis and if these symptoms occur instruct them to discontinue metformin hydrochloride extended-release tablets and report these symptoms to their healthcare provider.</paragraph>
                        <paragraph>For each of the known and possible risk factors for metformin-associated lactic acidosis, recommendations to reduce the risk of and manage metformin-associated lactic acidosis are provided below: </paragraph>
                        <list listType="unordered" ID="ID421" styleCode="Disc">
                           <item>
                              <content styleCode="bold">
                                 <content styleCode="italics">Renal Impairment</content>
                              </content>
                           </item>
                        </list>
                        <paragraph ID="ID422">The postmarketing metformin-associated lactic acidosis cases primarily occurred in patients with significant renal impairment. The risk of metformin accumulation and metformin-associated lactic acidosis increases with the severity of renal impairment because metformin is substantially excreted by the kidney. Clinical recommendations based upon the patient's renal function include <content styleCode="italics">[see DOSAGE AND ADMINISTRATION (<linkHtml href="#ID276">2.2</linkHtml>) and CLINICAL PHARMACOLOGY (<linkHtml href="#ID362">12.3</linkHtml>)]:</content>
                        </paragraph>
                        <list listType="unordered" ID="ID301" styleCode="Disc">
                           <item>Before initiating metformin hydrochloride extended-release      tablets, obtain an estimated glomerular filtration rate (eGFR).</item>
                           <item>Metformin hydrochloride extended-release tablets are      contraindicated in patients with an eGFR less than 30 mL/minute/1.73 m<sup>2</sup>
                              <content styleCode="italics">[see CONTRAINDICATIONS (<linkHtml href="#ID289">4</linkHtml>)]</content> .</item>
                           <item>Initiation of metformin hydrochloride extended-release      tablets is not recommended in patients with eGFR between 30 to 45      mL/minute/1.73 m<sup>2</sup>.</item>
                           <item>Obtain an eGFR at least annually in all patients taking metformin      hydrochloride extended-release tablets. In patients at increased risk for      the development of renal impairment (e.g., the elderly), renal function      should be assessed more frequently.</item>
                           <item>In patients taking metformin hydrochloride      extended-release tablets whose eGFR later falls below 45 mL/minute/1.73 m<sup>2</sup>,      assess the benefit and risk of continuing therapy.</item>
                        </list>
                        <list listType="unordered" ID="ID423" styleCode="Disc">
                           <item>
                              <content styleCode="bold">
                                 <content styleCode="italics">Drug Interactions</content>
                              </content>
                           </item>
                        </list>
                        <paragraph ID="ID424">The concomitant use of metformin hydrochloride extended-release tablets with specific drugs may increase the risk of metformin-associated lactic acidosis: those that impair renal function, result in significant hemodynamic change, interfere with acid-base balance or increase metformin accumulation <content styleCode="italics">[see DRUG INTERACTIONS (<linkHtml href="#ID321">7</linkHtml>)]. </content>Therefore, consider more frequent monitoring of patients. </paragraph>
                        <list listType="unordered" ID="ID425" styleCode="Disc">
                           <item>
                              <content styleCode="bold">
                                 <content styleCode="italics">Age      65 or Greater</content>
                              </content>
                           </item>
                        </list>
                        <paragraph ID="ID426">The risk of metformin-associated lactic acidosis increases with the patient's age because elderly patients have a greater likelihood of having hepatic, renal, or cardiac impairment than younger patients. Assess renal function more frequently in elderly patients <content styleCode="italics">[see USE IN SPECIFIC POPULATIONS (<linkHtml href="#ID347">8.5</linkHtml>)]. </content>
                        </paragraph>
                        <list listType="unordered" ID="ID427" styleCode="Disc">
                           <item>
                              <content styleCode="bold">
                                 <content styleCode="italics">Radiological      Studies with Contrast</content>
                              </content>
                           </item>
                        </list>
                        <paragraph ID="ID428">Administration of intravascular iodinated contrast agents in metformin-treated patients has led to an acute decrease in renal function and the occurrence of lactic acidosis. Stop metformin hydrochloride extended-release tablets at the time of, or prior to, an iodinated contrast imaging procedure in patients with an eGFR between 30 and 60 mL/minute/1.73 m<sup>2</sup>; in patients with a history of hepatic impairment, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast. Re-evaluate eGFR 48 hours after the imaging procedure, and restart metformin hydrochloride extended-release tablets if renal function is stable. </paragraph>
                        <list listType="unordered" ID="ID429" styleCode="Disc">
                           <item>
                              <content styleCode="bold">
                                 <content styleCode="italics">Surgery      and Other Procedures</content>
                              </content>
                           </item>
                        </list>
                        <paragraph ID="ID430">Withholding of food and fluids during surgical or other procedures may increase the risk for volume depletion, hypotension and renal impairment. Metformin hydrochloride extended-release tablets should be temporarily discontinued while patients have restricted food and fluid intake. </paragraph>
                        <list listType="unordered" ID="ID431" styleCode="Disc">
                           <item>
                              <content styleCode="bold">
                                 <content styleCode="italics">Hypoxic      States</content>
                              </content>
                           </item>
                        </list>
                        <paragraph ID="ID432">Several of the postmarketing cases of metformin-associated lactic acidosis occurred in the setting of acute congestive heart failure (particularly when accompanied by hypoperfusion and hypoxemia). Cardiovascular collapse (shock), acute myocardial infarction, sepsis, and other conditions associated with hypoxemia have been associated with lactic acidosis and may also cause prerenal azotemia. When such events occur, discontinue metformin hydrochloride extended-release tablets. </paragraph>
                        <list listType="unordered" ID="ID433" styleCode="Disc">
                           <item>Â  <content styleCode="bold">
                                 <content styleCode="italics">Excessive Alcohol Intake</content>
                              </content>
                           </item>
                        </list>
                        <paragraph ID="ID434">Alcohol potentiates the effect of metformin on lactate metabolism, and this may increase the risk of metformin-associated lactic acidosis. Warn patients against excessive alcohol intake while receiving metformin hydrochloride extended-release tablets.</paragraph>
                        <list listType="unordered" ID="ID435" styleCode="Disc">
                           <item>Â  <content styleCode="bold">
                                 <content styleCode="italics">Hepatic Impairment </content>
                              </content>
                           </item>
                        </list>
                        <paragraph ID="ID436">Patients with hepatic impairment have developed cases of metformin-associated lactic acidosis. This may be due to impaired lactate clearance resulting in higher lactate blood levels. Therefore, avoid use of metformin hydrochloride extended-release tablets in patients with clinical or laboratory evidence of hepatic disease.</paragraph>
                     </text>
                     <effectiveTime value="20250305"/>
                  </section>
               </component>
               <component>
                  <section ID="ID303">
                     <id root="74b8ffc8-d1e0-417f-99a1-52249964a3dd"/>
                     <title>5.2 Vitamin B<sub>12</sub> Deficiency</title>
                     <text>
                        <paragraph ID="ID304">In clinical trials of 29-week duration with metformin HCl tablets, a decrease to subnormal levels of previously normal serum vitamin B<sub>12</sub> levels was observed in approximately 7% of patients. Such decrease, possibly due to interference with B<sub>12</sub> absorption from the B<sub>12</sub>-intrinsic factor complex, may be associated with anemia but appears to be rapidly reversible with discontinuation of metformin or vitamin B<sub>12</sub> supplementation. Certain individuals (those with inadequate vitamin B<sub>12 </sub>or calcium intake or absorption) appear to be predisposed to developing subnormal vitamin B<sub>12 </sub>levels. Measure hematologic parameters on an annual basis and vitamin B<sub>12 </sub>at 2 to 3 year intervals in patients on metformin hydrochloride and manage any abnormalities <content styleCode="italics">[see ADVERSE REACTIONS (<linkHtml href="#ID313">6.1</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20181203"/>
                  </section>
               </component>
               <component>
                  <section ID="ID305">
                     <id root="a0bd6785-77e0-4658-957f-5c294d21e94b"/>
                     <title>5.3 Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues</title>
                     <text>
                        <paragraph ID="ID306">Insulin and insulin secretagogues (e.g., sulfonylurea) are known to cause hypoglycemia. Metformin hydrochloride may increase the risk of hypoglycemia when combined with insulin and/or an insulin secretagogue. Therefore, a lower dose of insulin or insulin secretagogue may be required to minimize the risk of hypoglycemia when used in combination with metformin hydrochloride <content styleCode="italics">[see DRUG INTERACTIONS (<linkHtml href="#ID321">7</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20181203"/>
                  </section>
               </component>
               <component>
                  <section ID="ID307">
                     <id root="2300292f-e9c5-450d-9ea0-11e61dd4434c"/>
                     <title>5.4 Macrovascular Outcomes</title>
                     <text>
                        <paragraph ID="ID308">There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with metformin hydrochloride.</paragraph>
                     </text>
                     <effectiveTime value="20181203"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID309">
               <id root="8aedb428-9674-45fe-9221-21db5b44bf87"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <effectiveTime value="20250305"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID311">Adverse reactions occurring &gt;5% in metformin hydrochloride clinical trials: hypoglycemia, diarrhea, and nausea. (<linkHtml href="#ID313">6.1</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Lupin Pharmaceuticals, Inc. at 1-800-399-2561 or FDA at 1-800-FDA-1088 or <content styleCode="italics">
                                 <content styleCode="underline">www.fda.gov/medwatch</content>.</content>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID312">
                     <id root="7f9c73da-2227-42d5-8f59-f0dd2a6a7ed2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID314">The following adverse reactions are discussed in more detail in other sections of the labeling: </paragraph>
                        <list listType="unordered" ID="ID315" styleCode="Disc">
                           <item>Lactic Acidosis <content styleCode="italics">[see <linkHtml href="#ID256">BOXED      WARNING</linkHtml> and WARNINGS AND PRECAUTIONS (<linkHtml href="#ID299">5.1</linkHtml>)] </content>
                           </item>
                           <item>Vitamin B<sub>12</sub>Deficiency <content styleCode="italics">[see WARNINGS AND      PRECAUTIONS (<linkHtml href="#ID303">5.2</linkHtml>)] </content>
                           </item>
                           <item>Hypoglycemia <content styleCode="italics">[see WARNINGS AND PRECAUTIONS (<linkHtml href="#ID305">5.3</linkHtml>)] </content>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20181203"/>
                  </section>
               </component>
               <component>
                  <section ID="ID313">
                     <id root="367de022-1d5d-4bb9-a822-e8566a34f54a"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph ID="ID316">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. </paragraph>
                        <paragraph>In clinical trials conducted in the U.S., over 1,000 patients with type 2 diabetes mellitus have been treated with metformin hydrochloride extended-release tablets 1,500 to 2,000 mg/day in active-controlled and placebo-controlled studies with the 500 mg dosage form. In the add-on to sulfonylurea study, patients receiving background glyburide therapy were randomized to receive add-on treatment of either one of three different regimens of metformin hydrochloride extended-release tablets or placebo. In total, 431 patients received metformin hydrochloride extended-release tablets and glyburide and 144 patients received placebo and glyburide. Adverse reactions reported in greater than 5% of patients treated with metformin hydrochloride extended-release tablets that were more common in the combined metformin hydrochloride extended-release tablets and glyburide group than in the placebo and glyburide group are shown in Table 1. In 0.7% of patients treated with metformin hydrochloride extended-release tablets and glyburide, diarrhea was responsible for discontinuation of study medication compared to no patients in the placebo and glyburide group.</paragraph>
                        <table ID="ID317" width="97%" styleCode="Noautorules">
                           <caption>  Table 1: Adverse Reactions Reported by &gt;5%<sup>*</sup> of Patients for the Combined Metformin HydrochlorideExtended-Release TabletsGroups Versus Placebo Group </caption>
                           <col width="27%"/>
                           <col width="39%"/>
                           <col width="33%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="3">
                                    <paragraph styleCode="Footnote">
                                       <content styleCode="bold">
                                          <sup>*</sup>
                                       </content>
                                       <content styleCode="bold">  Â Â Â  </content> Adverse reactions that were more common in the metformin hydrochloride extended-release tablets-treated than in the placebo-treated patients.</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td valign="top" styleCode="Lrule Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Adverse Reaction</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Metformin Hydrochloride Extended-Release Tablets   + Glyburide</content>
                                    <br/>
                                    <content styleCode="bold"> (n = 431)</content>
                                    <br/>
                                 </td>
                                 <td valign="bottom" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Placebo + Glyburide</content>
                                    <br/>
                                    <content styleCode="bold"> (n = 144)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Hypoglycemia<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 14%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 5%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Diarrhea<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 13%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 6%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Nausea<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 7%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 4%<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID318">
                           <content styleCode="italics">Laboratory Tests</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Vitamin B<sub>12</sub> Concentrations:</content>
                           </content>
                        </paragraph>
                        <paragraph>In clinical trials of 29-week duration with metformin HCl tablets, a decrease to subnormal levels of previously normal serum vitamin B<sub>12</sub> levels was observed in approximately 7% of patients.</paragraph>
                     </text>
                     <effectiveTime value="20181203"/>
                  </section>
               </component>
               <component>
                  <section ID="ID319">
                     <id root="9595bad2-7710-41bf-82d1-d9942ee34f6f"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph ID="ID320">The following adverse reactions have been identified during post-approval use of metformin hydrochloride extended-release tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. </paragraph>
                        <paragraph>Cholestatic, hepatocellular, and mixed hepatocellular liver injury have been reported with postmarketing use of metformin.</paragraph>
                     </text>
                     <effectiveTime value="20181203"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID321">
               <id root="3e901e61-169c-47c9-a05c-9d0ab9fac8f4"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20181203"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID323" styleCode="Disc">
                           <item>Carbonic anhydrase inhibitors      may increase risk of lactic acidosis. Consider more frequent monitoring. (<linkHtml href="#ID321">7</linkHtml>)</item>
                           <item>Drugs that reduce metformin      clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine)      may increase the accumulation of metformin. Consider the benefits and      risks of concomitant use. (<linkHtml href="#ID321">7</linkHtml>)</item>
                           <item>Alcohol can potentiate the      effect of metformin on lactate metabolism. Warn patients against excessive      alcohol intake. (<linkHtml href="#ID321">7</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID324">
                     <id root="0128c40f-a020-4621-bfb3-de695752cdaf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID437">Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. </paragraph>
                        <table ID="ID438" width="0" styleCode="Noautorules">
                           <caption>  Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets </caption>
                           <col width="135"/>
                           <col width="488"/>
                           <tbody>
                              <tr>
                                 <td colspan="2" valign="top" styleCode="Lrule Toprule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Carbonic Anhydrase Inhibitors </content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="italics">Clinical Impact:</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis. <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="italics">Intervention:</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Consider more frequent monitoring of these patients. <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="italics">Examples:</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Topiramate, zonisamide, acetazolamide or dichlorphenamide. <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Drugs that Reduce Metformin Hydrochloride Extended-Release Tablets Clearance </content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="italics">Clinical Impact:</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors) could increase systemic exposure to metformin and may increase the risk for lactic acidosis <content styleCode="italics">[see CLINICAL PHARMACOLOGY (<linkHtml href="#ID362">12.3</linkHtml>)]. </content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="italics">Intervention:</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Consider the benefits and risks of concomitant use with metformin hydrochloride extended-release tablets. <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="italics">Examples:</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Ranolazine, vandetanib, dolutegravir, and cimetidine. <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Alcohol </content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="italics">Clinical Impact:</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Alcohol is known to potentiate the effect of metformin on lactate metabolism. <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="italics">Intervention:</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Warn patients against excessive alcohol intake while receiving metformin hydrochloride extended-release tablets. <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Insulin Secretagogues or Insulin </content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="italics">Clinical Impact:</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="left"> Coadministration of metformin hydrochloride extended-release tablets with an insulin secretagogue (e.g., sulfonylurea) or insulin may increase the risk of hypoglycemia. <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="italics">Intervention:</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Patients receiving an insulin secretagogue or insulin may require lower doses of the insulin secretagogue or insulin. <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Drugs Affecting Glycemic Control </content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="italics">Clinical Impact:</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Certain drugs tend to produce hyperglycemia and may lead to loss of glycemic control. <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="italics">Intervention:</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> When such drugs are administered to a patient receiving metformin hydrochloride extended-release tablets, observe the patient closely for loss of blood glucose control. When such drugs are withdrawn from a patient receiving metformin hydrochloride extended-release tablets, observe the patient closely for hypoglycemia. <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="italics">Examples:</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. <br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20181203"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID335">
               <id root="031e736e-f8bd-4848-a2be-bbf27dc3f389"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20181203"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID337" styleCode="Disc">
                           <item>Females and Males of      Reproductive Potential: Advise premenopausal females of the potential for      an unintended pregnancy. (<linkHtml href="#ID343">8.3</linkHtml>)</item>
                           <item>Geriatric Use: Assess renal      function more frequently. (<linkHtml href="#ID347">8.5</linkHtml>)</item>
                           <item>Hepatic Impairment: Avoid use      in patients with hepatic impairment. (<linkHtml href="#ID351">8.7</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID338">
                     <id root="9f7a98ee-369f-4cd9-8cf3-6a3cd3f69a68"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <effectiveTime value="20170621"/>
                  </section>
               </component>
               <component>
                  <section ID="ID339">
                     <id root="d18ee93d-4316-457e-8aad-67945e02436e"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph ID="ID340">
                           <content styleCode="bold">
                              <content styleCode="italics">Risk Summary</content>
                           </content>
                        </paragraph>
                        <paragraph>Limited data with metformin hydrochloride in pregnant women are not sufficient to determine a drug-associated risk for major birth defects or miscarriage. Published studies with metformin use during pregnancy have not reported a clear association with metformin and major birth defect or miscarriage risk <content styleCode="italics">[see Data]</content>. There are risks to the mother and fetus associated with poorly controlled diabetes mellitus in pregnancy <content styleCode="italics">[see Clinical Considerations].</content>
                        </paragraph>
                        <paragraph>No adverse developmental effects were observed when metformin was administered to pregnant Sprague Dawley rats and rabbits during the period of organogenesis at doses up to 3 and 1 times, respectively, a 2,000 mg clinical dose, based on body surface area <content styleCode="italics">[see Data].</content>
                        </paragraph>
                        <paragraph>The estimated background risk of major birth defects is 6 to 10% in women with pregestational diabetes mellitus with an HbA1c &gt;7 and has been reported to be as high as 20 to 25% in women with an HbA1c &gt;10. The estimated background risk of miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Clinical Considerations</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Disease-associated maternal and/or embryo/fetal risk:</content>
                           </content>
                        </paragraph>
                        <paragraph>Poorly controlled diabetes mellitus in pregnancy increases the maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, stillbirth and delivery complications. Poorly controlled diabetes mellitus increases the fetal risk for major birth defects, stillbirth, and macrosomia-related morbidity.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Data</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Human Data:</content>
                           </content>
                        </paragraph>
                        <paragraph>Published data from post-marketing studies have not reported a clear association with metformin and major birth defects, miscarriage, or adverse maternal or fetal outcomes when metformin was used during pregnancy. However, these studies cannot definitely establish the absence of any metformin-associated risk because of methodological limitations, including small sample size and inconsistent comparator groups.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Animal Data:</content>
                           </content>
                        </paragraph>
                        <paragraph>Metformin HCl was not teratogenic or embyrolethal when administered to rats prior to pregnancy through the period of organogenesis at doses up to 900 mg/kg, or when administered to rabbits during the period of organogenesis at doses up to 90 mg/kg.</paragraph>
                     </text>
                     <effectiveTime value="20181203"/>
                  </section>
               </component>
               <component>
                  <section ID="ID341">
                     <id root="aad6fbe2-4140-4f37-b483-cfe8b0590b86"/>
                     <code code="34079-4" codeSystem="2.16.840.1.113883.6.1" displayName="LABOR &amp; DELIVERY SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph ID="ID342">
                           <content styleCode="bold">
                              <content styleCode="italics">Risk Summary</content>
                           </content>
                        </paragraph>
                        <paragraph>Limited published studies report that metformin is present in human milk <content styleCode="italics">[see Data]</content>. However, there is insufficient information to determine the effects of metformin on the breastfed infant and no available information on the effects of metformin on milk production. Therefore, the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for metformin hydrochloride and any potential adverse effects on the breastfed child from metformin hydrochloride or from the underlying maternal condition.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Data</content>
                           </content>
                        </paragraph>
                        <paragraph>Published clinical lactation studies report that metformin is present in human milk which resulted in infant doses approximately 0.11% to 1% of the maternal weight-adjusted dosage and a milk/plasma ratio ranging between 0.13 and 1. However, the studies were not designed to definitely establish the risk of use of metformin during lactation because of small sample size and limited adverse event data collected in infants.</paragraph>
                     </text>
                     <effectiveTime value="20181203"/>
                  </section>
               </component>
               <component>
                  <section ID="ID343">
                     <id root="bffcdb20-149d-47e2-aaf3-0b808ef80b6d"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>8.3 Females and Males of Reproductive Potential</title>
                     <text>
                        <paragraph ID="ID344">Discuss the potential for unintended pregnancy with premenopausal women as therapy with metformin hydrochloride may result in ovulation in some anovulatory women. </paragraph>
                     </text>
                     <effectiveTime value="20181203"/>
                  </section>
               </component>
               <component>
                  <section ID="ID345">
                     <id root="ed32826e-e41b-41e2-90c1-d152d2fbac7c"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph ID="ID346">Safety and effectiveness of metformin hydrochloride in pediatric patients have not been established. </paragraph>
                     </text>
                     <effectiveTime value="20181203"/>
                  </section>
               </component>
               <component>
                  <section ID="ID347">
                     <id root="f296ad45-5a17-4fad-83c5-0e9d96553f77"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph ID="ID348">Clinical studies of metformin hydrochloride did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy and the higher risk of lactic acidosis. Assess renal function more frequently in elderly patients. <content styleCode="italics">[see DOSAGE AND ADMINISTRATION (<linkHtml href="#ID276">2.2</linkHtml>) </content>and<content styleCode="italics"> WARNINGS AND PRECAUTIONS (<linkHtml href="#ID299">5.1</linkHtml>).]</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20181203"/>
                  </section>
               </component>
               <component>
                  <section ID="ID349">
                     <id root="0aa8121a-f616-40b2-bef0-41288decd517"/>
                     <title>8.6 Renal Impairment</title>
                     <text>
                        <paragraph ID="ID350">Metformin is substantially excreted by the kidney, and the risk of metformin accumulation and lactic acidosis increases with the degree of renal impairment. Metformin hydrochloride extended-release tablets are contraindicated in severe renal impairment, patients with an estimated glomerular filtration rate (eGFR) below 30 mL/minute/1.73 m<sup>2</sup>. <content styleCode="italics">[see DOSAGE AND ADMINISTRATION (<linkHtml href="#ID276">2.2</linkHtml>), CONTRAINDICATIONS (<linkHtml href="#ID289">4</linkHtml>), WARNINGS AND PRECAUTIONS (<linkHtml href="#ID299">5.1</linkHtml>) and CLINICAL PHARMACOLOGY (<linkHtml href="#ID362">12.3</linkHtml>).] </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20181203"/>
                  </section>
               </component>
               <component>
                  <section ID="ID351">
                     <id root="0aeccf3b-92da-45cc-81e2-1eeb86310740"/>
                     <title>8.7 Hepatic Impairment</title>
                     <text>
                        <paragraph ID="ID352">Use of metformin in patients with hepatic impairment has been associated with some cases of lactic acidosis. Metformin hydrochloride extended-release tablets are not recommended in patients with hepatic impairment<content styleCode="bold">. </content>
                           <content styleCode="italics">[see WARNINGS AND PRECAUTIONS (<linkHtml href="#ID299">5.1</linkHtml>)]</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20181203"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID353">
               <id root="60f79145-32da-4bf0-b317-b2443e76ca23"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph ID="ID354">Overdose of metformin HCl has occurred, including ingestion of amounts greater than 50 grams. Hypoglycemia was reported in approximately 10% of cases, but no causal association with metformin has been established. Lactic acidosis has been reported in approximately 32% of metformin overdose cases. <content styleCode="italics">[see WARNINGS AND PRECAUTIONS (<linkHtml href="#ID299">5.1</linkHtml>)]</content> Metformin is dialyzable with a clearance of up to 170 mL/minute under good hemodynamic conditions. Therefore, hemodialysis may be useful for removal of accumulated drug from patients in whom metformin overdosage is suspected.</paragraph>
               </text>
               <effectiveTime value="20250305"/>
            </section>
         </component>
         <component>
            <section ID="ID355">
               <id root="ccdf85dd-9104-4466-9294-c706297d4329"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph ID="ID356">Metformin hydrochloride extended-release tablets, USP contains the biguanide antihyperglycemic agent metformin in the form of monohydrochloride salt. The chemical name of metformin hydrochloride is N,N-dimethylimidodicarbonimidic diamide hydrochloride. The structural formula is as shown: </paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph ID="ID358">Metformin hydrochloride is a white to off-white crystalline compound with a molecular formula of C<sub>4</sub>H<sub>11</sub>N<sub>5</sub>â€¢HCl and a molecular weight of 165.63. Metformin hydrochloride is freely soluble in water and is practically insoluble in acetone, ether, and chloroform. The pKa of metformin is 12.4. The pH of a 1% aqueous solution of metformin hydrochloride is 6.68. </paragraph>
                  <paragraph>Metformin hydrochloride extended-release tablets, USP contain 500 mg or 1,000 mg of metformin hydrochloride, which is equivalent to 389.93 mg or 779.86 mg metformin, respectively. Each tablet contains ammonio methacrylate copolymer, colloidal silicon dioxide, dibutyl sebacate, hypromellose, magnesium stearate, microcrystalline cellulose, povidone and talc. </paragraph>
                  <paragraph>Metformin hydrochloride extended-release tablets USP, 500 mg meets USP Dissolution Test 13. FDA approved dissolution test specification differ from USP for Metformin hydrochloride extended-release tablets USP, 1000 mg.</paragraph>
               </text>
               <effectiveTime value="20250310"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Image-01</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="14bf5106-3b8c-4375-8466-c158c8f8f614-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID359">
               <id root="74b2bb3b-a579-4442-916e-d320419b2a70"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250305"/>
               <component>
                  <section ID="ID360">
                     <id root="d0899d52-ef8a-4e3f-8ff3-89a4f46f40a1"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph ID="ID361">Metformin is a biguanide that improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. With metformin therapy, insulin secretion remains unchanged while fasting insulin levels and day-long plasma insulin response may decrease.</paragraph>
                     </text>
                     <effectiveTime value="20181203"/>
                  </section>
               </component>
               <component>
                  <section ID="ID362">
                     <id root="5c9641e8-2bd0-471e-90a7-4174d34e03bf"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph ID="ID363">
                           <content styleCode="bold">
                              <content styleCode="italics">Absorption </content>
                           </content>
                        </paragraph>
                        <paragraph>Following a single oral dose of 1,000 mg (2x500 mg tablets) metformin hydrochloride extended-release tablets after a meal, the time to reach maximum plasma metformin concentration (T<sub>max</sub>) is achieved at approximately 7 to 8 hours. In both single- and multiple-dose studies in healthy subjects, once daily 1,000 mg (2x500 mg tablets) dosing provides equivalent systemic exposure, as measured by area under the-curve (AUC), and up to 35% higher C<sub>max</sub>, of metformin relative to the immediate release given as 500 mg twice daily.Â  At usual clinical doses and dosing schedules of metformin, steady state plasma concentrations of metformin are reached within 24 to 48 hours and are generally &lt;1 mcg/mL.</paragraph>
                        <paragraph>In a two-way, single-dose, crossover study in healthy volunteers, the 1,000 mg tablet was found to be similar to two 500 mg tablets under fed conditions based on equivalent C<sub>max</sub> and AUCs for the two formulations.</paragraph>
                        <paragraph>Single oral doses of metformin hydrochloride extended-release tablets from 500 mg to 2,500 mg resulted in less than proportional increase in both AUC and C<sub>max</sub>. </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Effect of food:</content>
                           </content>
                        </paragraph>
                        <paragraph>Low-fat and high-fat meals increased the systemic exposure (as measured by AUC) from metformin hydrochloride extended-release tablets by about 38% and 73%, respectively, relative to fasting. Both meals prolonged metformin T<sub>max </sub>by approximately 3 hours but C<sub>max</sub> was not affected.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Distribution</content>
                           </content>
                        </paragraph>
                        <paragraph>The apparent volume of distribution (V/F) of metformin following single oral doses of 850 mg metformin HCl averaged 654 Â± 358 L. Metformin is negligibly bound to plasma proteins. Metformin partitions into erythrocytes, most likely as a function of time. </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Metabolism</content>
                           </content>
                        </paragraph>
                        <paragraph>Intravenous, single-dose studies in healthy subjects demonstrate that metformin is excreted unchanged in the urine and does not undergo hepatic metabolism (no metabolites have been identified in humans), nor biliary excretion. </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Excretion</content>
                           </content>
                        </paragraph>
                        <paragraph>Renal clearance is approximately 3.5 times greater than creatinine clearance, which indicates that tubular secretion is the major route of metformin elimination. Following oral administration, approximately 90% of the absorbed drug is eliminated via the renal route within the first 24 hours, with a plasma elimination half-life of approximately 6.2 hours. In blood, the elimination half-life is approximately 17.6 hours, suggesting that the erythrocyte mass may be a compartment of distribution.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Special Populations</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Renal Impairment:</content>
                           </content>
                        </paragraph>
                        <paragraph>Following a single-dose administration of metformin hydrochloride extended-release tablets,  500 mg in subjects with mild and moderate renal impairment, the oral and renal clearance of metformin were decreased by 33% and 50% and 16% and 53%, respectively. Metformin peak and systemic exposure was 27% and 61% greater, respectively in subjects with mild renal impairment and 74% and 2.36-fold greater in subjects with moderate renal impairment as compared to healthy subjects.<content styleCode="italics"> [see DOSAGE AND ADMINISTRATION (<linkHtml href="#ID276">2.2</linkHtml>), CONTRAINDICATIONS (<linkHtml href="#ID289">4</linkHtml>), and WARNINGS AND PRECAUTIONS (<linkHtml href="#ID299">5.1</linkHtml>)]</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Hepatic Impairment:</content>
                           </content>
                        </paragraph>
                        <paragraph>No pharmacokinetic studies of metformin hydrochloride extended-release tablets have been conducted in subjects with hepatic impairment, <content styleCode="italics">[see WARNINGS AND PRECAUTIONS (<linkHtml href="#ID299">5.1</linkHtml>) and USE IN SPECIFIC POPULATIONS (<linkHtml href="#ID351">8.7</linkHtml>)]</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Geriatrics:</content>
                           </content>
                        </paragraph>
                        <paragraph>Limited data from controlled pharmacokinetic studies of metformin HCl in healthy elderly subjects suggest that total plasma clearance of metformin is decreased by 35%, the half-life is prolonged by 64% and C<sub>max</sub> is increased by 76%, compared to healthy young subjects. From these data, it appears that the change in metformin pharmacokinetics with aging is primarily accounted for by a change in renal function. <content styleCode="italics">[see DOSAGE AND ADMINISTRATION (<linkHtml href="#ID270">2</linkHtml>) and WARNINGS AND PRECAUTIONS (<linkHtml href="#ID299">5.1</linkHtml>)]</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Gender:</content>
                           </content>
                        </paragraph>
                        <paragraph>In the pharmacokinetic studies in healthy volunteers, there were no important differences between male and female subjects with respect to metformin AUC and t<sub>1/2</sub>. However, C<sub>max </sub>for metformin was 40% higher in female subjects as compared to males. In controlled clinical studies in patients with type 2 diabetes, the antihyperglycemic effect of metformin HCl tablets was comparable in males and females. The gender differences for C<sub>max</sub> are unlikely to be clinically important. </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Race:</content>
                           </content>
                        </paragraph>
                        <paragraph>A suggested trend towards 10 % higher metformin C<sub>max </sub>and AUC values for metformin are obtained in Asian subjects when compared to Caucasian, Hispanic and Black subjects. The differences between the Asian and Caucasian groups are unlikely to be clinically important. In controlled clinical studies of metformin HCl in patients with type 2 diabetes, the antihyperglycemic effect was comparable in whites (n = 249), blacks (n = 51) and Hispanics (n = 24).</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Pediatrics:</content>
                           </content>
                        </paragraph>
                        <paragraph>There are no available pharmacokinetic data with metformin hydrochloride extended-release tablets in pediatric patients.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Drug Interactions</content>
                           </content>
                        </paragraph>
                        <paragraph>Specific pharmacokinetic drug interaction studies with metformin hydrochloride extended-release tablets have not been performed except for one with glyburide. However, such studies have been performed on metformin HCl tablets.</paragraph>
                        <table ID="ID364" width="100%" styleCode="Noautorules">
                           <caption>  Table 3: Â Â Â Â Â  Effect of Coadministered Drug on Plasma Metformin Systemic Exposure </caption>
                           <col width="20%"/>
                           <col width="19%"/>
                           <col width="20%"/>
                           <col width="19%"/>
                           <col width="20%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="5">
                                    <paragraph styleCode="Footnote">1. All metformin HCl and coadministered drugs were given as single doses.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="5">
                                    <paragraph styleCode="Footnote">2. AUC = AUC<sub>0-inf</sub>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="5">
                                    <paragraph styleCode="Footnote">3. Ratio of arithmetic means</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="5">
                                    <paragraph styleCode="Footnote">4. Metformin hydrochloride extended-release tablets 500 mg</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="5">
                                    <paragraph styleCode="Footnote">5. At steady state with topiramate 100 mg every 12 hours and metformin 500 mg every 12 hours; AUC = AUC<sub>0-12h</sub>
                                    </paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td rowspan="2" valign="top" styleCode="Lrule Toprule Botrule Rrule" align="left"> Coadministered Drug<br/>
                                 </td>
                                 <td rowspan="2" valign="top" styleCode=" Toprule Botrule Rrule" align="left"> Dose of Coadministered<br/> Drug<sup>1</sup>
                                    <br/>
                                 </td>
                                 <td rowspan="2" valign="top" styleCode=" Toprule Botrule Rrule" align="left"> Dose of Metformin HCl<sup>1</sup>
                                    <br/>
                                 </td>
                                 <td colspan="2" valign="top" styleCode=" Toprule Botrule Rrule" align="left"> Geometric Mean Ratio (ratio with/without coadministered drug)<br/> No Effect = 1.00<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> AUC<sup>2</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="left"> C<sub>max</sub>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="5" valign="top" styleCode="Lrule Botrule Rrule" align="left"> No dosing adjustments required for the following:<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Glyburide<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 5 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 500 mg<sup>4</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0.98<sup>3</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> 0.99<sup>3</sup>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Furosemide<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 40 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 850 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1.09<sup>3</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> 1.22<sup>3</sup>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Nifedipine<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 10 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 850 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1.16<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> 1.21<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Propranolol<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 40 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 850 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0.90<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> 0.94<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Ibuprofen<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 400 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 850 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1.05<sup>3</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> 1.07<sup>3</sup>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="5" valign="top" styleCode="Lrule Botrule Rrule" align="left"> Cationic drugs that are eliminated by renal tubular secretion may increase the accumulation of metformin: [<content styleCode="italics">see </content>
                                    <content styleCode="italics">WARNINGS AND PRECAUTIONS (5.1) </content>
                                    <content styleCode="italics">and </content>
                                    <content styleCode="italics">DRUG INTERACTIONS (7)</content> ]<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Cimetidine<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 400 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 850 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1.40<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> 1.61<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="5" valign="top" styleCode="Lrule Botrule Rrule" align="left"> Carbonic anhydrase inhibitors may cause metabolic acidosis: <br/> [<content styleCode="italics">see</content>
                                    <content styleCode="italics"> WARNINGS AND PRECAUTIONS (5.1) </content>
                                    <content styleCode="italics">and </content>
                                    <content styleCode="italics">DRUG INTERACTIONS (7)</content> ]<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Topiramate<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 100 mg<sup>5</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 500 mg<sup>5</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1.25<sup>5</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> 1.17<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <table ID="ID365" width="100%" styleCode="Noautorules">
                           <caption>  Table 4: Â Â Â Â Â  Effect of Metformin on Coadministered Drug Systemic Exposure </caption>
                           <col width="20%"/>
                           <col width="19%"/>
                           <col width="19%"/>
                           <col width="20%"/>
                           <col width="20%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="5">
                                    <paragraph styleCode="Footnote">
                                       <sup>1</sup> All metformin HCl and coadministered drugs were given as single doses.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="5">
                                    <paragraph styleCode="Footnote">
                                       <sup>2</sup> AUC = AUC<sub>0-inf</sub> unless otherwise noted</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="5">
                                    <paragraph styleCode="Footnote">
                                       <sup>3</sup> Ratio of arithmetic means, p-value of difference &lt; 0.05</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="5">
                                    <paragraph styleCode="Footnote">
                                       <sup>4</sup> AUC<sub>0-24</sub>
                                       <sub>hr</sub> reported</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="5">
                                    <paragraph styleCode="Footnote">
                                       <sup>5</sup> Ratio of arithmetic means</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td rowspan="2" valign="top" styleCode="Lrule Toprule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Coadministered Drug</content>
                                    <br/>
                                 </td>
                                 <td rowspan="2" valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Dose of Coadministered</content>
                                    <br/>
                                    <content styleCode="bold"> Drug<sup>1</sup>
                                    </content>
                                    <br/>
                                 </td>
                                 <td rowspan="2" valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Dose of Metformin HCl<sup>1</sup>
                                    </content>
                                    <br/>
                                 </td>
                                 <td colspan="2" valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Geometric Mean Ratio </content>
                                    <br/>
                                    <content styleCode="bold"> (ratio with/without coadministered drug)</content>
                                    <br/>
                                    <content styleCode="bold"> No effect = 1</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> AUC<sup>2</sup>
                                    </content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> C<sub>max</sub>
                                    </content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="5" valign="top" styleCode="Lrule Botrule Rrule" align="left"> No dosing adjustments required for the following:<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Glyburide<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 5 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 500 mg<sup>4</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0.78<sup>3</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0.63<sup>3</sup>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Furosemide<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 40 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 850 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0.87<sup>3</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0.69<sup>3</sup>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Nifedipine<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 10 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 850 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1.10<sup>4</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1.08<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Propranolol<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 40 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 850 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1.01<sup>4</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0.94<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Ibuprofen<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 400 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 850 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0.97<sup>5</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1.01<sup>5</sup>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Cimetidine<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 400 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 850 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0.95<sup>4</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1.01<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250305"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID366">
               <id root="29a955cf-8863-445b-934c-d1e9ddb15a20"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20191201"/>
               <component>
                  <section ID="ID367">
                     <id root="7e411005-2f7f-4c0d-8bce-2bf53a22c827"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph ID="ID368">Long-term carcinogenicity studies have been performed in Sprague Dawley rats at doses of 150, 300, and 450 mg/kg/day in males and 150, 450, 900, and 1,200 mg/kg/day in females. These doses are approximately 2, 4, and 8 times in males, and 3, 7, 12, and 16 times in females of the maximum recommended human daily dose of 2,000 mg based on body surface area comparisons. No evidence of carcinogenicity with metformin was found in either male or female rats. A carcinogenicity study was also performed in Tg.AC transgenic mice at doses up to 2,000 mg applied dermally. No evidence of carcinogenicity was observed in male or female mice.</paragraph>
                        <paragraph>Genotoxicity assessments in the Ames test, gene mutation test (mouse lymphoma cells), chromosomal aberrations test (human lymphocytes) and in vivo mouse micronucleus tests were negative. Fertility of male or female rats was not affected by metformin when administered at doses up to 600 mg/kg/day, which is approximately 3 times the maximum recommended human daily dose based on body surface area comparisons.</paragraph>
                     </text>
                     <effectiveTime value="20191201"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID369">
               <id root="f659e48b-5266-4dd6-9bc0-2481ccb35d73"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph ID="ID370">In a multicenter, randomized, double-blind, active-controlled, dose-ranging, parallel group study conducted in patients type 2 diabetes mellitus, metformin hydrochloride extended-release tablets 1,500 mg once daily, metformin hydrochloride extended-release tablets 1,500 per day in divided doses (500 mg in the morning and 1,000 mg in the evening), and metformin hydrochloride extended-release tablets 2,000 mg once daily were compared to immediate-release metformin HCl tablets 1,500 mg per day in divided doses (500 mg in the morning and 1,000 mg in the evening). This study included patients (n = 338) who were newly diagnosed with diabetes, patients treated only with diet and exercise, patients treated with a single antidiabetic medication (sulfonylureas, alpha-glucosidase inhibitors, thiazolidinediones, or meglitinides), and patients (n = 368) receiving metformin HCl tablets up to 1,500 mg/day plus a sulfonylurea at a dose equal to or less than one-half the maximum dose. Patients who were enrolled on monotherapy or combination antidiabetic therapy underwent a 6-week washout. Patients randomized to metformin hydrochloride extended-release tablets began titration from 1,000 mg/day up to their assigned treatment dose over 3 weeks. Patients randomized to immediate-release metformin initiated 500 mg twice daily for 1 week followed by 500 mg with breakfast and 1,000 mg with dinner for the second week. The 3-week treatment period was followed by an additional 21-week period at the randomized dose. The results are presented in Table 4.</paragraph>
                  <table ID="ID371" width="0" styleCode="Noautorules">
                     <caption>  Table 5: Mean Changes from Baseline in HbA1c and Fasting Plasma Glucose at Week 24 Comparing Metformin Hydrochloride Extended-Release Tablets versus Metformin HCl Tablets* in Patients with Type 2 Diabetes Mellitus </caption>
                     <col width="237"/>
                     <col width="94"/>
                     <col width="94"/>
                     <col width="94"/>
                     <col width="110"/>
                     <tfoot>
                        <tr>
                           <td align="left" colspan="5">
                              <paragraph styleCode="Footnote">* Immediate-release metformin HCl tablets</paragraph>
                           </td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr>
                           <td rowspan="2" valign="top" styleCode="Lrule Toprule Botrule Rrule" align="left">
                              <br/>
                           </td>
                           <td colspan="3" valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                              <content styleCode="bold"> Metformin Hydrochloride </content>
                              <br/>
                              <content styleCode="bold"> Extended-Release Tablets</content>
                              <br/>
                           </td>
                           <td rowspan="2" valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                              <content styleCode="bold"> Metformin HCl Tablets*</content>
                              <br/>
                              <content styleCode="bold"> 1,500 mg in  Divided Doses</content>
                              <br/>
                              <content styleCode="bold"> (n = 174)</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode=" Botrule Rrule" align="center">
                              <content styleCode="bold"> 1,500 mg </content>
                              <br/>
                              <content styleCode="bold"> Once Daily </content>
                              <br/>
                              <content styleCode="bold"> (n = 178)</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                              <content styleCode="bold"> 1,500 mg </content>
                              <br/>
                              <content styleCode="bold"> in Divided Doses   (n = 182)</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                              <content styleCode="bold"> 2,000 mg</content>
                              <br/>
                              <content styleCode="bold"> Once Daily</content>
                              <br/>
                              <content styleCode="bold"> (n =172)</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="bold"> HbA1c (%), N</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> 169<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> 175<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> 159<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> 170<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Baseline<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> 8.2<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> 8.5<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> 8.3<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> 8.7<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Mean Change at Final Visit<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> -0.7<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> -0.7<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> -1.1<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> -0.7<br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule Rrule" align="left"> Mean Difference from Metformin HCl Tablets* (98.4% CI)<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> 0 (-0.3, 0.3)<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> 0 (-0.3, 0.3)<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> -0.4 (-0.7, -0.1)<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> N/A<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="bold"> Fasting Plasma Glucose (mg/dL), </content>
                              <content styleCode="bold"> N</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> 175<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> 179<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> 170<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> 172<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Baseline<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> 190 <br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> 192.3 <br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> 184 <br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> 197 <br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Mean Change at Final Visit<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> -39 <br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> -32 <br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> -42 <br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> -32 <br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule Rrule" align="left"> Mean Difference from Metformin HCl Tablets* (95% CI)<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> -6 (-15, 2)<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> 0 (-8, 9)<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> -10 (-19, -1)<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> N/A<br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph ID="ID372">Mean baseline body weight was 88.2 kg, 90.5 kg, 87.7 kg and 88.7 kg in the metformin hydrochloride extended-release tablets 1,500 mg once daily, metformin hydrochloride extended-release tablets 1,500 mg in divided doses, metformin hydrochloride extended-release tablets 2,000 mg once daily and metformin HCl tablets 1,500 mg in divided doses arms, respectively. Mean change in body weight from baseline to week 24 was -0.9 kg, -0.7 kg, -1.1 kg, and -0.9 kg in the metformin hydrochloride extended-release tablets 1,500 mg once daily, metformin hydrochloride extended-release tablets 1,500 mg in divided doses, metformin hydrochloride extended-release tablets 2,000 mg once daily and metformin HCl tablets 1,500 mg in divided doses arms, respectively.</paragraph>
                  <paragraph>A double-blind, randomized, placebo-controlled (glyburide add-on) multicenter study enrolled patients with type 2 diabetes mellitus who were newly diagnosed or treated with diet and exercise (n = 144), or who were receiving monotherapy with metformin, sulfonylureas, alpha-glucosidase inhibitors, thiazolidinediones, or meglitinides, or treated with combination therapy consisting of metformin HCl/glyburide at doses up to 1,000 mg metformin + 10 mg glyburide per day (or equivalent doses of glipizide or glimepiride up to half the maximum therapeutic dose) (n = 431). All patients were stabilized on glyburide for a 6-week run-in period, and then randomized to 1 of 4 treatments: placebo + glyburide (glyburide alone); metformin hydrochloride extended-release tablets 1,500 mg once a day + glyburide, metformin hydrochloride extended-release tablets 2,000 mg once a day + glyburide, or metformin hydrochloride extended-release tablets 1,000 mg twice a day + glyburide. A 3-week metformin hydrochloride extended-release tablets titration period was followed by a 21-week maintenance treatment period. Use of insulin and oral hypoglycemic agents other than the study drugs were prohibited. The results are presented in Table 5</paragraph>
                  <table ID="ID373" width="100%" styleCode="Noautorules">
                     <caption>  Table 6: Mean Changes from Baseline in HbA1c and Fasting Plasma Glucose at Week 24 for the Metformin Hydrochloride Extended-Release Tablets+Glyburide Groups and Placebo+Glyburide Treatment Group in Patients with Type 2 Diabetes Mellitus </caption>
                     <col width="29%"/>
                     <col width="16%"/>
                     <col width="21%"/>
                     <col width="15%"/>
                     <col width="17%"/>
                     <tfoot>
                        <tr>
                           <td align="left" colspan="5">
                              <paragraph styleCode="Footnote">* Glyburide was administered as 10 mg at breakfast and 5 mg at dinner.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" colspan="5">
                              <paragraph styleCode="Footnote">
                                 <sup>a </sup>p-value for pairwise comparison &lt;0.001</paragraph>
                           </td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr>
                           <td valign="top" styleCode="Lrule Toprule Rrule" align="left">
                              <br/>
                           </td>
                           <td colspan="3" valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                              <content styleCode="bold"> Metformin Hydrochloride Extended-Release  Tablets + Glyburide*</content>
                              <br/>
                           </td>
                           <td rowspan="2" valign="bottom" styleCode=" Toprule Botrule Rrule" align="center">
                              <content styleCode="bold"> Placebo+ Glyburide*</content>
                              <br/>
                              <content styleCode="bold"> (n = 144)</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center">
                              <content styleCode="bold"> 1,500 mg </content>
                              <br/>
                              <content styleCode="bold"> Once Daily</content>
                              <br/>
                              <content styleCode="bold"> (n =144)</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                              <content styleCode="bold"> 1,000 mg </content>
                              <br/>
                              <content styleCode="bold"> Twice Daily</content>
                              <br/>
                              <content styleCode="bold"> (n = 141)</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                              <content styleCode="bold"> 2,000 mg </content>
                              <br/>
                              <content styleCode="bold"> Once Daily</content>
                              <br/>
                              <content styleCode="bold"> (n = 146)</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="bold"> HbA</content> 1c <content styleCode="bold"> (%), N</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> 136<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> 136<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> 144<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> 141<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Baseline<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> 7.9<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> 7.8<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> 7.7<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> 8.1<br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule Rrule" align="left"> Mean Change at Final Visit<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> -0.7<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> -0.8<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> -0.7<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> -0.1<br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule Rrule" align="left"> Mean Difference from Glyburide Alone (95% CI)<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> -0.8<sup> a</sup> (-1.0, -0.6)<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> -0.9<sup> a</sup> (-1.1, -0.7)<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> -0.8<sup>a</sup> (-1.0, -0.6)<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> N/A<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="bold"> Fasting Plasma Glucose (mg/dL), </content>
                              <content styleCode="bold"> N</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> 143<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> 141<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> 145<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> 144<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Baseline<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> 163<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> 163<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> 159<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> 164<br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule Rrule" align="left"> Mean Change at Final Visit<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> -14<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> -16<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> -9<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> 16<br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule Rrule" align="left"> Mean Difference from Glyburide Alone (95 % CI)<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> -29.2<sup> a</sup> (-39, -20)<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> -31.2<sup> a</sup> (-41, -22)<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> -24.9<sup> a</sup> (-35, -15)<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> N/A<br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph ID="ID374">Mean baseline body weight was 89.4 kg, 103.7 kg, 102.9 kg and 95.6 kg in the metformin hydrochloride extended-release tablets 1,500 mg once daily, metformin hydrochloride extended-release tablets 1,500 mg in divided doses, metformin hydrochloride extended-release tablets 2,000 mg once daily and metformin HCl tablets 1,500 mg in divided doses arms, respectively. Mean change in body weight from baseline to week 24 was 0.3 kg, 0.1 kg, 0 kg, and 0.7 kg in the metformin hydrochloride extended-release tablets 1,500 mg once daily, metformin hydrochloride extended-release tablets 1,500 mg in divided doses, metformin hydrochloride extended-release tablets 2,000 mg once daily and metformin HCl tablets 1,500 mg in divided doses arms, respectively.</paragraph>
               </text>
               <effectiveTime value="20181203"/>
            </section>
         </component>
         <component>
            <section ID="ID375">
               <id root="2d7dcc98-8fe5-4982-b401-b225415d014d"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph ID="ID376">Metformin hydrochloride extended-release tablets USP, 500 mg are available as white to off-white, oval shaped, biconvex coated tablet, debossed with "L41" on one side and "LU" on the other side.</paragraph>
                  <paragraph>Metformin hydrochloride extended-release tablets USP, 1,000 mg are available as white to off-white, oval shaped, biconvex coated tablet, debossed with "L42" on one side and "LU" on the other side.</paragraph>
                  <paragraph>They are supplied as follows:</paragraph>
                  <table ID="ID377" width="511" styleCode="Noautorules">
                     <caption/>
                     <col width="139"/>
                     <col width="171"/>
                     <col width="201"/>
                     <tbody>
                        <tr>
                           <td valign="top" align="left">
                              <content styleCode="bold"> Strength</content>
                              <br/>
                           </td>
                           <td valign="top" align="left">
                              <content styleCode="bold"> Package</content>
                              <br/>
                           </td>
                           <td valign="top" align="left">
                              <content styleCode="bold"> NDC Code</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" align="left"> 500 mg<br/>
                           </td>
                           <td valign="top" align="left"> Bottles of 100<br/>
                           </td>
                           <td valign="top" align="left"> 68180-338-01<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" align="left"> 1,000 mg<br/>
                           </td>
                           <td valign="top" align="left"> Bottles of 90<br/>
                           </td>
                           <td valign="top" align="left"> 68180-339-09<br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph ID="ID378">Store at 25Â°C (77Â°F); excursions permitted to 15Â° to 30Â°C (59Â° to 86Â°F); [see USP Controlled Room Temperature]. </paragraph>
               </text>
               <effectiveTime value="20250305"/>
            </section>
         </component>
         <component>
            <section ID="ID379">
               <id root="6c10ac9a-855e-40e1-b396-e18601ff530a"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph ID="ID380">Advise the patient to read the FDA-approved patient labeling (Patient Information).</paragraph>
                  <paragraph>
                     <content styleCode="italics">Lactic Acidosis</content>
                  </paragraph>
                  <paragraph>Explain the risks of lactic acidosis, its symptoms, and conditions that predispose to its development. Advise patients to discontinue metformin hydrochloride extended-release tablets immediately and to promptly notify their healthcare provider if unexplained hyperventilation, myalgias, malaise, unusual somnolence or other nonspecific symptoms occur. Counsel patients against excessive alcohol intake and inform patients about importance of regular testing of renal function while receiving metformin hydrochloride extended-release tablets. Instruct patients to inform their doctor that they are taking metformin hydrochloride extended-release tablets prior to any surgical or radiological procedure, as temporary discontinuation may be required <content styleCode="italics">[see WARNINGS AND PRECAUTIONS (<linkHtml href="#ID299">5.1</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">Hypoglycemia </content>
                  </paragraph>
                  <paragraph>Inform patients that hypoglycemia may occur when metformin hydrochloride extended-release tablets are coadministered with oral sulfonylureas and insulin. Explain to patients receiving concomitant therapy the risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development <content styleCode="italics">[see WARNINGS AND PRECAUTIONS (<linkHtml href="#ID305">5.3</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">Vitamin B<sub>12</sub> Deficiency</content>
                  </paragraph>
                  <paragraph>Inform patients about importance of regular hematological parameters while receiving metformin hydrochloride extended-release tablets <content styleCode="italics">[see WARNINGS AND PRECAUTIONS (<linkHtml href="#ID303">5.2</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Females of Reproductive Age</content>
                  </paragraph>
                  <paragraph>Inform females that treatment with metformin hydrochloride extended-release tablets may result in ovulation in some premenopausal anovulatory women which may lead to unintended pregnancy <content styleCode="italics">[see USE IN SPECIFIC POPULATIONS (<linkHtml href="#ID343">8.3</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Administration Information</content>
                  </paragraph>
                  <paragraph>Inform patients that metformin hydrochloride extended-release tablets must be swallowed whole and not crushed, cut, or chewed, and that the inactive ingredients may occasionally be eliminated in the feces as a soft mass that may resemble the original tablet.</paragraph>
                  <paragraph>LUPIN and the <renderMultiMedia referencedObject="IMGID3801"/>Â are registered trademarks of Lupin Pharmaceuticals, Inc.</paragraph>
                  <paragraph>Manufactured for:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Lupin Pharmaceuticals, Inc.</content>
                  </paragraph>
                  <paragraph>Naples, FL 34108</paragraph>
                  <paragraph>United States</paragraph>
                  <paragraph>
                     <content styleCode="bold">MADE IN INDIA</content>
                  </paragraph>
                  <paragraph>Revised: January 2025Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  ID #: 277358</paragraph>
               </text>
               <effectiveTime value="20250310"/>
               <component>
                  <observationMedia ID="IMGID3801">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="14bf5106-3b8c-4375-8466-c158c8f8f614-380-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID383">
               <id root="c61b7edf-b994-45e2-91e6-08715bb1b93a"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <text>
                  <paragraph ID="ID384">
                     <content styleCode="bold">PATIENT INFORMATION</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Metformin Hydrochloride Extended-Release Tablets USP</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(met-FOR-min HYE-droe-KLOR-ide)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">What is the most important information I should know about metformin hydrochloride extended-release tablets?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Metformin hydrochloride extended-release tablets can cause serious side effects, including:</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Lactic acidosis.</content>Â <content styleCode="bold">Metformin hydrochloride, the medicine in metformin hydrochloride extended-release tablets can cause a rare, but serious side effect called lactic acidosis (a buildup of lactic acid in the blood) that can cause death. Lactic acidosis is a medical emergency and must be treated in the hospital.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Stop taking metformin hydrochloride extended-release tablets and call your doctor right away if you get any of the following symptoms of lactic acidosis:</content>
                  </paragraph>
                  <list listType="unordered" ID="ID385" styleCode="Disc">
                     <item>feel very weak and tired</item>
                     <item>have unusual (not normal)      muscle pain</item>
                     <item>have trouble breathing</item>
                     <item>have unexplained stomach or      intestinal problems with nausea and vomiting, or diarrhea</item>
                     <item>have unusual sleepiness or      sleep longer than usual</item>
                     <item>feel cold, especially in your      arms and legs</item>
                     <item>feel dizzy or lightheaded</item>
                     <item>have a slow or irregular      heartbeat</item>
                  </list>
                  <paragraph ID="ID386">
                     <content styleCode="bold">You have a higher chance of getting lactic acidosis if you:</content>
                  </paragraph>
                  <list listType="unordered" ID="ID387" styleCode="Disc">
                     <item>have severe kidney problems. See<content styleCode="bold">"Do not take metformin hydrochloride extended-release tablets if you"</content>
                     </item>
                     <item>have liver problems.</item>
                     <item>drink a lot of alcohol (very often or short-term "binge" drinking).</item>
                     <item>get dehydrated (lose a large amount of body fluids). This can happen if you are sick with a fever, vomiting, or diarrhea. Dehydration can also happen when you sweat a lot with activity or exercise and do not drink enough fluids.</item>
                     <item>have certain x-ray tests with injectable dyes or contrast agents.</item>
                     <item>have surgery or other procedure for which you need to restrict the amount of food and liquid you eat and drink.</item>
                     <item>have congestive heart failure.</item>
                     <item>have a heart attack, severe infection, or stroke.</item>
                     <item>are 65 years of age or older.</item>
                  </list>
                  <paragraph ID="ID388">Tell your doctor if you have any of the problems in the list above. </paragraph>
                  <paragraph>Tell your doctor that you are taking metformin hydrochloride extended-release tablets before you have surgery or x-ray tests. Your doctor may need to stop metformin hydrochloride extended-release tablets for a while if you have surgery or certain x-ray tests. </paragraph>
                  <paragraph>Metformin hydrochloride extended-release tablets can have other serious side effects. See <content styleCode="bold">"What are the possible side effects of metformin hydrochloride extended-release tablets?"</content>.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What is metformin hydrochloride extended-release tablet?</content>
                  </paragraph>
                  <list listType="unordered" ID="ID389" styleCode="Disc">
                     <item>Metformin hydrochloride      extended-release tablet is a prescription medicine that contains metformin      hydrochloride. Metformin hydrochloride extended-release tablet is used      with diet and exercise to help control high blood sugar (hyperglycemia) in      adults with type 2 diabetes.</item>
                  </list>
                  <paragraph ID="ID390">It is not known if metformin hydrochloride extended-release tablet is safe and effective in children.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not take metformin hydrochloride extended-release tablets if you: </content>
                  </paragraph>
                  <list listType="unordered" ID="ID391" styleCode="Disc">
                     <item>have severe kidney problems</item>
                     <item>are allergic to the metformin hydrochloride in metformin      hydrochloride extended-release tablets or any of the ingredients in      metformin hydrochloride extended-release tablets. See the end of this      leaflet for a list of ingredients in metformin hydrochloride      extended-release tablets.</item>
                     <item>have a condition called metabolic acidosis or diabetic      ketoacidosis (increased ketones in your blood or urine).</item>
                  </list>
                  <paragraph ID="ID392">
                     <content styleCode="bold">Before taking metformin hydrochloride extended-release tablets tell your doctor about all of your medical conditions, including if you:</content>
                  </paragraph>
                  <list listType="unordered" ID="ID393" styleCode="Disc">
                     <item>have a history or risk for      diabetic ketoacidosis. See <content styleCode="bold">"Do not take metformin hydrochloride      extended-release tablets if you:".</content>
                     </item>
                     <item>have kidney problems.</item>
                     <item>have liver problems.</item>
                     <item>have heart problems, including      congestive heart failure.</item>
                     <item>are 65 years of age or older.</item>
                     <item>drink alcohol very often, or      drink a lot of alcohol in short-term "binge" drinking.</item>
                     <item>are taking insulin or a      sulfonylurea medicine.</item>
                     <item>are pregnant or plan to become      pregnant. It is not known if metformin hydrochloride extended-release      tablets can harm your unborn baby. If you are pregnant, talk with your      doctor about the best way to control your blood sugar while you are      pregnant.</item>
                     <item>are a woman who has not gone      through menopause (premenopausal) who does not have periods regularly or      at all. Metformin hydrochloride extended-release tablets can cause the      release of an egg from an ovary in a woman (ovulation). This can increase      your chance of getting pregnant.</item>
                     <item>are breastfeeding or plan to      breastfeed. Metformin hydrochloride can pass into your breast milk. Talk      with your doctor about the best way to feed your baby while you take      metformin hydrochloride extended-release tablets.</item>
                  </list>
                  <paragraph ID="ID394">
                     <content styleCode="bold">Tell your doctor about all the medicines you take</content>, including prescription and over-the-counter medicines, vitamins and herbal supplements. Know the medicines you take. Keep a list of them to show your doctor and pharmacist. Talk to your doctor before you start any new medicine. </paragraph>
                  <paragraph>Metformin hydrochloride extended-release tablets may affect the way other medicines work, and other medicines may affect how metformin hydrochloride extended-release tablets works.</paragraph>
                  <paragraph>
                     <content styleCode="bold">How should I take metformin hydrochloride extended-release tablets? </content>
                  </paragraph>
                  <list listType="unordered" ID="ID395" styleCode="Disc">
                     <item>Take metformin hydrochloride      extended-release tablets exactly as your doctor tells you.</item>
                     <item>Metformin hydrochloride      extended-release tablets should be taken 1 time each day with your evening      meal to help decrease an upset stomach.</item>
                     <item>Swallow metformin hydrochloride      extended-release tablets whole. Do not crush, cut, or chew the tablets.</item>
                     <item>You may sometimes pass a soft      mass in your stools (bowel movement) that looks like metformin      hydrochloride extended-release tablets. This is normal and will not affect      the way metformin hydrochloride extended-release tablets works.</item>
                     <item>When your body is under some      type of stress, such as fever, trauma (such as a car accident), infection,      or surgery, the amount of diabetes medicine that you need may change. Tell      your doctor right away if you have any of these problems.</item>
                     <item>Your doctor should do blood      tests to check how well your kidneys are working before and during your      treatment with metformin hydrochloride extended-release tablets.</item>
                     <item>Your doctor will check your      diabetes with regular blood tests, including your blood sugar levels and      your hemoglobin A1C.</item>
                     <item>Low blood sugar (hypoglycemia)      can happen more often when metformin hydrochloride extended-release      tablets are taken with certain other diabetes medicines. Talk to your      doctor about how to prevent, recognize, and manage low blood sugar. See "<content styleCode="bold">What      are the possible side effects of metformin hydrochloride extended-release      tablets?</content> ".</item>
                     <item>Check your blood sugar as your      doctor tells you to.</item>
                     <item>Stay on your prescribed diet      and exercise program while taking metformin hydrochloride extended-release      tablets.</item>
                     <item>If you miss a dose of metformin      hydrochloride extended-release tablets, take your next dose at the normal      schedule. Do not take 2 doses of metformin hydrochloride extended-release      tablets on the same day.</item>
                     <item>If you take too much metformin      hydrochloride extended-release tablets, call your doctor or go to the      nearest hospital emergency room right away.</item>
                  </list>
                  <paragraph ID="ID396">
                     <content styleCode="bold">What should I avoid while taking metformin hydrochloride extended-release tablets?</content>
                  </paragraph>
                  <paragraph>Do not drink a lot of alcoholic drinks while taking metformin hydrochloride extended-release tablets. This means you should not binge drink for short periods, and you should not drink a lot of alcohol on a regular basis. Alcohol can increase the chance of getting lactic acidosis.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What are the possible side effects of metformin hydrochloride extended-release tablets?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Metformin hydrochloride extended-release tablets can cause serious side effects, including:</content>
                  </paragraph>
                  <list listType="unordered" ID="ID411" styleCode="Disc">
                     <item>See "<content styleCode="bold">What is the most important information I should know about metformin hydrochloride extended-release tablets?</content> ".</item>
                     <item>
                        <content styleCode="bold">Low vitamin B<sub>12</sub>(vitamin B<sub>12</sub>deficiency).</content> Using metformin hydrochloride extended-release tablets may cause a decrease in the amount of vitamin B<sub>12</sub>in your blood, especially if you have had low vitamin B<sub>12</sub>levels before. Your doctor may do blood tests to check your vitamin B<sub>12</sub>levels.</item>
                     <item>
                        <content styleCode="bold">Low blood sugar (hypoglycemia). Low blood sugar is a serious, but common, side effect of metformin hydrochloride extended-release tablets.</content> If you take metformin hydrochloride extended-release tablets with another medicine that can cause low blood sugar, such as sulfonylureas or insulin, you have a higher risk of getting low blood sugar. The dose of your sulfonylurea medicine or insulin may need to be lowered while you take metformin hydrochloride extended-release tablets. Signs and symptoms of low blood sugar may include:<list listType="unordered" styleCode="Circle">
                           <item>headache</item>
                           <item>drowsiness</item>
                           <item>weakness</item>
                           <item>irritability</item>
                           <item>hunger</item>
                           <item>fast heartbeat</item>
                           <item>confusion</item>
                           <item>shaking or feeling jittery</item>
                           <item>dizziness</item>
                           <item>sweating</item>
                        </list>
                     </item>
                  </list>
                  <paragraph ID="ID412">
                     <content styleCode="bold">The most common side effects of metformin hydrochloride extended-release tablets include:</content>
                  </paragraph>
                  <list listType="unordered" ID="ID413" styleCode="Disc">
                     <item>diarrhea</item>
                     <item>nausea</item>
                  </list>
                  <paragraph ID="ID414">These are not all of the possible side effects of metformin hydrochloride extended-release tablets. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</paragraph>
                  <paragraph>
                     <content styleCode="bold">How should I store metformin hydrochloride extended-release tablets?</content>
                  </paragraph>
                  <paragraph>Store metformin hydrochloride extended-release tablets at room temperature between 68Â°F to 77Â°F (20Â°C to 25Â°C). </paragraph>
                  <paragraph>
                     <content styleCode="bold">Keep metformin hydrochloride extended-release tablets and all medicines out of the reach of children.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">General information about the safe and effective use of metformin hydrochloride extended-release tablets.</content>
                  </paragraph>
                  <paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use metformin hydrochloride extended-release tablets for a condition for which it was not prescribed. Do not give metformin hydrochloride extended-release tablets to other people, even if they have the same symptoms you have. It may harm them.</paragraph>
                  <paragraph>You can ask your pharmacist or doctor for information about metformin hydrochloride extended-release tablets that is written for health professionals</paragraph>
                  <paragraph>
                     <content styleCode="bold">What are the ingredients in metformin hydrochloride extended-release tablets?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Active Ingredient:</content> metformin hydrochloride</paragraph>
                  <paragraph>
                     <content styleCode="bold">Inactive Ingredient:</content> Each tablet contains ammonio methacrylate copolymer, colloidal silicon dioxide, dibutyl sebacate, hypromellose, magnesium stearate, microcrystalline cellulose, povidone and talc. </paragraph>
                  <paragraph>For more information, go to www.lupinpharmaceuticals.com or call 1-800-399-2561.</paragraph>
                  <paragraph>This Patient Information has been approved by the U.S. Food and Drug Administration.</paragraph>
                  <paragraph>LUPIN and the <renderMultiMedia referencedObject="IMGID4141"/>Â are registered trademarks of Lupin Pharmaceuticals, Inc.</paragraph>
                  <paragraph>Manufactured for:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Lupin Pharmaceuticals, Inc.</content>
                  </paragraph>
                  <paragraph>Naples, FL 34108</paragraph>
                  <paragraph>United States</paragraph>
                  <paragraph>
                     <content styleCode="bold">MADE IN INDIA</content>
                  </paragraph>
                  <paragraph>Revised: January 2025Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  ID #: 277359</paragraph>
               </text>
               <effectiveTime value="20250310"/>
               <component>
                  <observationMedia ID="IMGID4141">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="14bf5106-3b8c-4375-8466-c158c8f8f614-414-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID397">
               <id root="f8f4200b-aedf-4ed6-b8b1-710644551dca"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph ID="ID398">Metformin Hydrochloride Extended-Release Tablets USP </paragraph>
                  <paragraph>500 mg</paragraph>
                  <paragraph>Bottle Pack: 100 Tablets</paragraph>
                  <paragraph>NDC: 68180-338-01</paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
                  <paragraph ID="ID400">Metformin Hydrochloride Extended-Release Tablets USP </paragraph>
                  <paragraph>1000 mg</paragraph>
                  <paragraph>Bottle Pack: 90 Tablets</paragraph>
                  <paragraph>NDC: 68180-339-09</paragraph>
                  <renderMultiMedia referencedObject="MM3"/>
               </text>
               <effectiveTime value="20250310"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>image 2</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="14bf5106-3b8c-4375-8466-c158c8f8f614-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM3">
                     <text>Image-03</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="14bf5106-3b8c-4375-8466-c158c8f8f614-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>